ReviewDrug metabolism reviews2011
Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models.
Review in Drug metabolism reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- Efflux ABC transporters in drug disposition and their posttranscriptional gene regulation by microRNAs.Frontiers in pharmacology · 2024Review
- Assessing cytochrome P450 function using genetically engineered mouse models.Advances in pharmacology (San Diego, Calif.) · 2022Review
- Effects of total parenteral nutrition on drug metabolism gene expression in mice.Acta pharmaceutica Sinica. B · 2020Article
- Membrane transporter data to support kinetically-informed chemical risk assessment using non-animal methods: Scientific and regulatory perspectives.Environment international · 2019Review
- The safety evaluation of food flavouring substances: the role of metabolic studies.Toxicology research · 2018Review
- Sulfenylation of Human Liver and Kidney Microsomal Cytochromes P450 and Other Drug-Metabolizing Enzymes as a Response to Redox Alteration.Molecular & cellular proteomics : MCP · 2018Article
- Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants.Drug metabolism and disposition: the biological fate of chemicals · 2017Article
- New technologies in drug metabolism and toxicity screening: organ-to-organ interaction.Expert opinion on drug metabolism & toxicology · 2016Article
- Clinical pharmacokinetics and pharmacodynamics of clopidogrel.Clinical pharmacokinetics · 2015Review
- Development and characterization of a novel mouse line humanized for the intestinal peptide transporter PEPT1.Molecular pharmaceutics · 2014Article
- ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.Current pharmaceutical design · 2014Review
- Emerging applications of metabolomics in studying chemopreventive phytochemicals.The AAPS journal · 2013Review
- Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.Drug metabolism and disposition: the biological fate of chemicals · 2013Article
- LC-MS-based Metabolomics of Xenobiotic-induced Toxicities.Computational and structural biotechnology journal · 2013Review
- Humanized transgenic mouse models for drug metabolism and pharmacokinetic research.Current drug metabolism · 2011Article
- Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice.Drug metabolism and disposition: the biological fate of chemicals · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Determining the in vivo significance of a specific enzyme, transporter, or xenobiotic receptor in drug metabolism and pharmacokinetics may be hampered by gene multiplicity and complexity, levels of expression, and interaction between various components involved. The development of knockout (loss-of-function) and transgenic (gain-of-function) mouse models opens the door to the improved understanding of gene function in a whole-body system. There is also growing interest in the development of humanized mice to overcome species differences in drug metabolism and disposition. This review, therefore, aims to summarize and discuss some successful examples of drug-metabolizing enzyme, transporter, and nuclear-receptor genetically modified mouse models. These genetically modified mouse models have been proven as invaluable models for understanding in vivo function of drug-metabolizing enzymes, transporters, and xenobiotic receptors in drug metabolism and transport, as well as predicting potential drug-drug interaction and toxicity in humans. Nevertheless, concerns remain about interpretation of data obtained from such genetically modified mouse models, in which the expression of related genes is altered significantly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.